Original Article

You have full text access to this OnlineOpen article

Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy

Long-term results

  1. Donatella Tirindelli Danesi M.D.1,†,*,
  2. Giorgio Arcangeli M.D.2,
  3. Enrico Cruciani M.D.3,
  4. Pierluigi Altavista M.D.1,
  5. Antonella Mecozzi M.D.3,
  6. Bianca Saracino M.D.2,
  7. Filina Orefici M.D.3,4

Article first published online: 12 OCT 2004

DOI: 10.1002/cncr.20654

Issue

Cancer

Cancer

Volume 101, Issue 11, pages 2540–2548, 1 December 2004

Additional Information

How to Cite

Danesi, D. T., Arcangeli, G., Cruciani, E., Altavista, P., Mecozzi, A., Saracino, B. and Orefici, F. (2004), Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy. Cancer, 101: 2540–2548. doi: 10.1002/cncr.20654

Author Information

  1. 1

    Department of Biotechnologies, Health and Ecosystems Protection, Section of Toxicology and Biomedical Sciences, ENEA Casaccia, Rome, Italy

  2. 2

    Department of Medical Oncology, Division of Radiation Oncology, Regina Elena Cancer Institute, Rome, Italy

  3. 3

    Division of Urology and Oncology Unit, Fatebenefratelli Hospital, Isola Tiberina, Rome, Italy

  4. 4

    Department of Surgery Pietro Valdoni, University La Sapienza, Rome, Italy

  1. †

    Fax: (011) 39-06-30486559

*Section of Toxicology and Biomedical Sciences, ENEA, CR Casaccia, Via Anguillarese, 301, 00060 Roma, Italy

Publication History

  1. Issue published online: 16 NOV 2004
  2. Article first published online: 12 OCT 2004
  3. Manuscript Revised: 10 AUG 2004
  4. Manuscript Accepted: 10 AUG 2004
  5. Manuscript Received: 21 APR 2004

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (104K)

REFERENCES

  • 1
    Kaufman DS, Shipley WU, Griffin PP, et al. Selective bladder preservation by combination treatment of invasive bladder cancer. N Engl J Med. 1993; 329: 1377–1382.
  • 2
    Dunst J, Sauer R, Schrott KM, et al. Organ-sparing treatment of advanced bladder cancer: a 10- year experience. Int J Radiat Oncol Biol Phys. 1994; 30/2: 261–266.
  • 3
    Tester W, Caplan R, Heaney J, et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol. 1996; 14: 119–126.
  • 4
    Chretien Y, Mejean A, Durdux C, et al. Infiltrating cancer of the bladder: can radiochemotherapy be an alternative to cystectomy? J Urol (Paris). 1996; 102: 3–8.
  • 5
    Kachnic L, Kaufmann DS, Heney NM, et al. Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol. 1997; 15: 1022–1029.
  • 6
    Dunst J, Rodel C, Zietman A, Schrott KM, Sauer R, Shipley WU. Bladder preservation in muscle-invasive bladder cancer by conservative surgery and radiochemotherapy. Semin Surg Oncol. 2001; 20: 24–32.
    Direct Link:
  • 7
    Rodel C, Grabenbauer GG, Kuhn R, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 2002; 20: 3061–3071.
  • 8
    Shipley WU, Kaufman DS, Tester WJ, Pilepich MV, Sandler HM: Radiation Therapy Oncology Group. Overview of bladder cancer trials in the Radiation Therapy Oncology Group. Cancer. 2003; 97(8 Suppl. ): 2115–2119.
    Direct Link:
  • 9
    Chretien Y, Oudard S, Durdux C. Bladder cancer: realities and perspectives. Bull Cancer. 2003; 90: 61–67.
  • 10
    Scher HI, Yagoda A, Herr HW, et al. Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion. J Urol. 1988; 139: 470–474.
  • 11
    Dreicer R, Kollmorgen TA, Smith RF, et al. Neoadjuvant cisplatin, methotrexate and vinblastin for muscle invasive bladder cancer: long-term follow-up. J Urol. 1993; 150: 849–852.
  • 12
    Shipley WU, Winter KA, Kaufman DS, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol. 1998; 16: 3576–3583.
  • 13
    Housset M, Maulard C, Chretien Y, et al. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol. 1993; 11: 2150–2157.
  • 14
    Tirindelli Danesi D, Arcangeli G, Cruciani E, et al. Combined treatment of invasive bladder carcinoma with transurethral resection, induction chemotherapy, and radical radiotherapy plus concomitant protracted infusion of cisplatin and 5-fluorouracil. A phase I study. Cancer. 1997; 80: 1464–1471.
    Direct Link:
  • 15
    Saracino B, Arcangeli G, Mecozzi A, et al. Combined hyperfractionated radiotherapy and protracted infusion chemotherapy in bladder cancer for organ preservation. Clin Ther. 1998; 149: 183–189.
  • 16
    Dewit L. Combined treatment of radiation and cis-diammine-dichloroplatinum (II): a review of experimental and clinical data. Int J Radiat Oncol Biol Phys. 1987; 13: 403–426.
  • 17
    Rosenthal CJ, Rotman M, Choi K, Sand J. Cisplatin by continuous infusion with concurrent radiation in malignant tumors (a phase I-II study). In: RosenthalCJ, RotmanM, editors. Clinical application of continuous infusion chemotherapy and concomitant radiation therapy. New York: Plenum Press, 1986: 177–180.
  • 18
    Russell KJ, Boileau MA, Higano C, et al. Combined 5-fluorouracil and irradiation for transitional cell carcinoma of the urinary bladder. Int J Radiat Oncol Biol Phys. 1990; 19: 693–699.
  • 19
    Byfield JE, Calabro-Jones P, Klisak I, et al. Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-FU or ftorafur and x-rays. Int J Radiat Oncol Biol Phys. 1982; 8: 1923–1933.
  • 20
    Byfield JE. Theoretical basis and clinical applications of 5-fluorouracil as a radiosensitizer. In: RosenthalCJ, RotmanM, editors. Clinical application of continuous infusion chemotherapy and concomitant radiation therapy. New York: Plenum Press, 1986: 113–124.
  • 21
    Keane TE, Gingrich JR, Rosner G, et al. Combination versus single agent therapy in effecting complete therapeutic response in human bladder cancer: analysis of cisplatin and/or 5-fluorouracil in an in vivo survival model. Cancer Res. 1994; 54: 475–481.
  • 22
    Arcangeli G, Tirindelli Danesi D. Concomitant combination of radiotherapy and protracted venous infusion of anticancer drugs. In: Monduzzi, editor. Fifth international meeting on progress in radio-oncology. Salzburg: International Proceedings Division, 1995: 35–40.
  • 23
    SobinLH, WittekindCH, editors. TNM classification of malignant tumors. 5th edition. New York: John Wiley & Sons, Inc., 1997.
  • 24
    Harker WA, Meyers FJ, Freiha FS, et al. Cisplatin, methotrexate and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract: a Northern California Oncology Group study. J Clin Oncol. 1985; 3: 1463–1470.
  • 25
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457–481.
  • 26
    Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001; 19: 666–675.
  • 27
    Sauer R, Birkenhake S, Kuhn R, et al. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer. Int J Radiat Oncol Biol Phys. 1998; 40: 121–127.
  • 28
    Edsmyr F, Andersson L, Esposti PL, Littbrand B, Nilsson B. Irradiation therapy with multiple small fractions per day in urinary bladder cancer. Radiother Oncol. 1985; 4: 197–203.
  • 29
    Maciejewski B, Makewski S. Dose fractionation and tumor repopulation in radiotherapy for bladder cancer. Radiother Oncol. 1991; 21: 163–170.
  • 30
    De Neve W, Lybeert MLM, Goor C, Crommelin M, Ribot JG. Radiotherapy for T2 and T3 carcinoma of the bladder: the influence of overall treatment time. Radiother Oncol. 1995; 36: 183–188.
  • 31
    Zietman AL, Shipley WU, Kaufman DS, et al. A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer. J Urol. 1998; 160: 1673–1677.
  • 32
    Mantyla M, Kortekangas AE, Valavaara RA, et al. Tumor regression during radiation treatment as a guide to prognosis. Br J Radiol. 1979; 52: 972–977.
  • 33
    Suit H, Lindberg R, Fletcher GH. Prognostic significance of extent of tumor regression at completion of radiation therapy. Radiology. 1965; 84: 1100–1105.
  • 34
    Moonen L, vd Voet H, de Nijs R, et al. Muscle-invasive bladder cancer treated with external beam radiotherapy: pretreatment prognostic factors and the predictive value of cystoscopic re-evaluation during treatment. Radiother Oncol. 1998; 49: 149–155.
  • 35
    Matos T, Cufer T, Cervek J, et al. Prognostic factors in invasive bladder carcinoma treated by combined modality protocol (organ-sparing approach). Int J Radiat Oncol Biol Phys. 2000; 46: 403–409.
  • 36
    Zietman AL, Sacco D, Skowronski U, et al. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. J Urol. 2003; 170: 1772–1776.
  • 37
    Hagan MP, Winter KA, Kaufman DS, et al. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys. 2003; 57: 665–672.
View Full Article (HTML) Get PDF (104K)